Buy-Side Battle: Technology opportunities in a post-Covid market
Our lens on the Buy Side technology opportunities to leverage in a rapidly shifting market Download to see more on: The data opportunity in the hunt for liquidity The role…
Where is the hidden profit in the portfolio’s product structure and pricing?
What will you do to narrow down the options for profitable growth, and deliver the plan to win?
How will you ensure the CDD thesis bleeds through to execution and is tracked?
How will you flip a company or asset’s business model to deliver recurring growth?
How do you answer the burning question “do I keep or do I kill?”
A multitude of actions could deliver growth but an unlimited pool leads to hedging options. This can stagnate growth, lead to spasmodic execution with no operational efficiency, or it can mean sticking to the ‘status quo’.
Identify the laser focus to deliver 10x growth and build the plan of execution to make it happen.
1775% ROI in three months due to new deals signed with our plan, in a new segment we identified. Previous revenue and conversion here was zero.
Pricing is the ultimate weapon to increase revenue and profit. Traditional metrics miss nuances which move you from 2x to 10x impact. This will maximise revenue today and guarantee maximum growth for every new product, R&D investment and feature until exit.
Build pricing based on value to increase conversion, revenue, profit and up-sell ability, then ensure it is executed to generate return.
~2x the value of an average annual license fee with no impact on conversion rate.
A deck alone is not decisive . Our tech market edge and bias to action will drive capital deployment. We answer your killer deciding question – “Can we make this technology the market leader?”
Build pricing based on value to increase conversion, revenue, profit and up-sell ability, then ensure it is executed to generate return.
For a firm looking to recapitalise, we identified the one value-driving aspect which was recapitalised and is now growing, and drove a sale of 90% of the asset.
B2B technology growth is not linear. We specialise in post-deal portfolio acceleration, which also includes:
– David Dawson, Investment Director at Pollen Street Capital
Technology is scalable and can deliver significant investor returns. But the commercialisation of technology makes the difference in-market.
Planning is half of the challenge. We translate this into action, delivering the “so what” in The Cockpit, enabling you to track performance against this. This creates real top-line results to expedite your portfolio’s performance.
– Chris Wittlinger, Investment Manager at RussMedia Equity partners
Our lens on the Buy Side technology opportunities to leverage in a rapidly shifting market Download to see more on: The data opportunity in the hunt for liquidity The role…
The role of Commercial Due Diligence is to drive a decision. But in a world where 60% of failed deals are attributed to DD oversights, CDD is clearly not a…
By injecting a bias of ‘action over decks,’ we have been the secret weapon for Private Equity deals in 2019. From our work accelerating 60+ B2B technology firms, one thing is…
The Clubhouse, 8 St James’s Square, London, SW1Y 4JU
© 2023 Cruxy&Co.